FRAX was developed to predict 10-year probability of major osteoporotic fracture (MOF) and hip fracture in the general population. Aromatase inhibitors (AI) used in breast cancer induce loss in bone mineral density (BMD) and are reported to increase fracture risk. AI exposure is not a direct input to FRAX but is captured under “secondary osteoporosis”. To inform use of FRAX in women treated with AI, we used a population-based registry for the Province of Manitoba, Canada, to identify women aged ≥40 years initiating AI for breast cancer with at least 12 months’ AI exposure (n = 1775), women with breast cancer not receiving AI (n = 1016), and women from the general population (n = 34,205). Among AI users, fracture probability estimated withou...
BACKGROUND: The impact of long-term adjuvant therapy with aromatase inhibitors (AIs) on vertebral f...
Aromatase inhibitors (AIs), the standard therapy for estrogen receptor- or progesterone receptor-pos...
Aromatase-inhibitors (AIs) are commonly used for treatment of patients with hormone-receptor positiv...
FRAX was developed to predict 10‐year probability of major osteoporotic fracture (MOF) and hip fract...
Background Aromatase inhibitors (AIs) used in breast cancer induce loss in bone mineral density (BMD...
Background. Aromatase inhibitors (AIs) used in breast cancer induce loss in bone mineral density (B...
Aromatase inhibitors have been associated with accelerated bone loss and an increased risk of osteop...
Aromatase inhibitors have been associated with accelerated bone loss and an increased risk of osteop...
International audienceBACKGROUND: The purpose of this study was to describe the fracture incidence a...
A cross-sectional study was performed to assess bone health history among aromatase inhibitor (AI) u...
BACKGROUND: Several guidelines have been reported for bone-directed treatment in women with early br...
Background: Several guidelines have been reported for bone-directed treatment in women with early br...
__Background__ Several guidelines have been reported for bone-directed treatment in women with early...
A cross-sectional study was performed to assess bone health history among aromatase inhibitor (AI) u...
Ten-year fracture risk assessment with the fracture risk assessment system (FRAX) is increasingly us...
BACKGROUND: The impact of long-term adjuvant therapy with aromatase inhibitors (AIs) on vertebral f...
Aromatase inhibitors (AIs), the standard therapy for estrogen receptor- or progesterone receptor-pos...
Aromatase-inhibitors (AIs) are commonly used for treatment of patients with hormone-receptor positiv...
FRAX was developed to predict 10‐year probability of major osteoporotic fracture (MOF) and hip fract...
Background Aromatase inhibitors (AIs) used in breast cancer induce loss in bone mineral density (BMD...
Background. Aromatase inhibitors (AIs) used in breast cancer induce loss in bone mineral density (B...
Aromatase inhibitors have been associated with accelerated bone loss and an increased risk of osteop...
Aromatase inhibitors have been associated with accelerated bone loss and an increased risk of osteop...
International audienceBACKGROUND: The purpose of this study was to describe the fracture incidence a...
A cross-sectional study was performed to assess bone health history among aromatase inhibitor (AI) u...
BACKGROUND: Several guidelines have been reported for bone-directed treatment in women with early br...
Background: Several guidelines have been reported for bone-directed treatment in women with early br...
__Background__ Several guidelines have been reported for bone-directed treatment in women with early...
A cross-sectional study was performed to assess bone health history among aromatase inhibitor (AI) u...
Ten-year fracture risk assessment with the fracture risk assessment system (FRAX) is increasingly us...
BACKGROUND: The impact of long-term adjuvant therapy with aromatase inhibitors (AIs) on vertebral f...
Aromatase inhibitors (AIs), the standard therapy for estrogen receptor- or progesterone receptor-pos...
Aromatase-inhibitors (AIs) are commonly used for treatment of patients with hormone-receptor positiv...